Micropapillary Lung Adenocarcinoma EGFR, K-ras, and BRAF Mutational Profile

被引:76
作者
Achcar, Rosane De Oliveira Duarte [1 ]
Nikiforova, Marina N. [1 ]
Yousem, Samuel A. [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA
关键词
Micropapillary adenocarcinoma; Papillary adenocarcinoma; Bronchioloalveolar adenocarcinoma; GROWTH-FACTOR RECEPTOR; DISTINCT PATHOLOGICAL MARKER; PROGNOSTIC-SIGNIFICANCE; HISTOLOGIC SUBTYPE; BRONCHIOLOALVEOLAR; GEFITINIB; PATTERN; SENSITIVITY; PAPILLARY; CANCER;
D O I
10.1309/AJCPBS85VJEOBPDO
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Micropapillary lung adenocarcinoma (MPA) has been reported as an aggressive variant of adenocarcinoma, frequently manifesting at high stage with a poor prognosis. We analyzed the clinical and molecular profile of 15 primary MPAs for K-ras, EGFR, and BRAF mutations and performed,fluorescence in situ hybridization for EGFR amplification. In our study, 11 (73%) of 75 MPAs harbored mutually exclusive mutations: 5 (33%) K-ras, 3 (20%) EGFR, and 3 (20%) BRA F. Mutations in all 3 genes occurred inpatients with a smoking history and tumors with mucinous differentiation and secondary lepidic, acinar, and solid growth, suggesting that in a Western population, cytomorphologic correlation with genetic mutations is more unpredictable than in Japanese cohorts. We conclude that K-ras, EGFR, and BRAF mutations are disproportionately seen in adenocarcinomas of lung with a dominant micropapillary growth pattern compared with conventional adenocarcinoma in our institutional experience.
引用
收藏
页码:694 / 700
页数:7
相关论文
共 31 条
  • [1] Prognostic analysis of pulmonary adenocarcinoma subclassification with special consideration of papillary and bronchioloalveolar types
    Aida, S
    Shimazaki, H
    Sato, K
    Sato, M
    Deguchi, H
    Ozeki, Y
    Tamai, S
    [J]. HISTOPATHOLOGY, 2004, 45 (05) : 468 - 476
  • [2] Micropapillary component in lung adenocarcinoma -: A distinctive histologic feature with possible prognostic significance
    Amin, MB
    Tamboli, P
    Merchant, SH
    Ordóñez, NG
    Ro, J
    Ayala, AG
    Ro, JY
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (03) : 358 - 364
  • [3] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Cappuzzo, F
    Hirsch, FR
    Rossi, E
    Bartolini, S
    Ceresoli, GL
    Bemis, L
    Haney, J
    Witta, S
    Danenberg, K
    Domenichini, I
    Ludovini, V
    Magrini, E
    Gregorc, V
    Doglioni, C
    Sidoni, A
    Tonato, M
    Franklin, WA
    Crino, L
    Bunn, PA
    Varella-Garcia, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09): : 643 - 655
  • [4] Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
    Chou, TY
    Chiu, CH
    Li, LH
    Hsiao, CY
    Tzen, CY
    Chang, KT
    Chen, YM
    Perng, RP
    Tsai, SF
    Tsai, CM
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (10) : 3750 - 3757
  • [5] New insight into BRAF mutations in cancer
    Dhomen, Nathalie
    Marais, Richard
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2007, 17 (01) : 31 - 39
  • [6] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    Eberhard, DA
    Johnson, BE
    Amler, LC
    Goddard, AD
    Heldens, SL
    Herbst, RS
    Ince, WL
    Jänne, PA
    Januario, T
    Johnson, DH
    Klein, P
    Miller, VA
    Ostland, MA
    Ramies, DA
    Sebisanovic, D
    Stinson, JA
    Zhang, YR
    Seshagiri, S
    Hillan, KJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5900 - 5909
  • [7] Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    Jackman, David M.
    Yeap, Beow Y.
    Sequist, Lecia V.
    Lindeman, Neal
    Holmes, Alison J.
    Joshi, Victoria A.
    Bell, Daphne W.
    Huberman, Mark S.
    Halmos, Balazs
    Rabin, Michael S.
    Haber, Daniel A.
    Lynch, Thomas J.
    Meyerson, Matthew
    Johnson, Bruce E.
    Jaenne, Pasi A.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 3908 - 3914
  • [8] Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma
    Kamiya, Kazunori
    Hayashi, Yuichiro
    Douguchi, Junya
    Hashiguchi, Akinori
    Yamada, Taketo
    Izumi, Yotaro
    Watanabe, Masazumi
    Kawamura, Masafumi
    Horinouchi, Hirohisa
    Shimada, Naoki
    Kobayashi, Koichi
    Sakamoto, Michiie
    [J]. MODERN PATHOLOGY, 2008, 21 (08) : 992 - 1001
  • [9] Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors
    Kawakami, Takehito
    Nabeshima, Kazuki
    Makimoto, Yoshifumi
    Hamasaki, Makoto
    Iwasaki, Akinori
    Shirakusa, Takayuki
    Iwasaki, Hiroshi
    [J]. MODERN PATHOLOGY, 2007, 20 (05) : 514 - 521
  • [10] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Lynch, TJ
    Bell, DW
    Sordella, R
    Gurubhagavatula, S
    Okimoto, RA
    Brannigan, BW
    Harris, PL
    Haserlat, SM
    Supko, JG
    Haluska, FG
    Louis, DN
    Christiani, DC
    Settleman, J
    Haber, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2129 - 2139